FDA Approves PLUVICTO — Novartis Pharmaceuticals Corporation

# FDA Approves Novartis's PLUVICTO for Prostate Cancer Treatment Novartis Pharmaceuticals Corporation received FDA approval for PLUVICTO (lutetium lu-177 vipivotide tetraxetan), a novel intravenous radiopharmaceutical for prostate cancer, potentially positioning the company to capture significant market share in the growing precision oncology segment. The approval of this targeted therapy addresses an underserved treatment category and could generate substantial revenue for Novartis while advancing the therapeutic landscape for advanced prostate cancer patients.